WO2010083611A1 - Procédé de prévention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimétique de l'apolipoprotéine-a1 (apoa1) - Google Patents

Procédé de prévention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimétique de l'apolipoprotéine-a1 (apoa1) Download PDF

Info

Publication number
WO2010083611A1
WO2010083611A1 PCT/CA2010/000108 CA2010000108W WO2010083611A1 WO 2010083611 A1 WO2010083611 A1 WO 2010083611A1 CA 2010000108 W CA2010000108 W CA 2010000108W WO 2010083611 A1 WO2010083611 A1 WO 2010083611A1
Authority
WO
WIPO (PCT)
Prior art keywords
diastolic dysfunction
subject
apoa1
mimetic peptide
controlling
Prior art date
Application number
PCT/CA2010/000108
Other languages
English (en)
Inventor
Jean-Claude Tardif
David Busseuil
Eric Rheaume
Original Assignee
Institut De Cardiologie De Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut De Cardiologie De Montreal filed Critical Institut De Cardiologie De Montreal
Priority to EP10733186A priority Critical patent/EP2389189A4/fr
Priority to CA2788223A priority patent/CA2788223A1/fr
Publication of WO2010083611A1 publication Critical patent/WO2010083611A1/fr
Priority to US13/185,737 priority patent/US20120021982A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to the general field of medical methods and compounds and is particularly concerned with a method and compound for the prevention and treatment of diastolic dysfunction.
  • administering the APOA1 mimetic peptide/phospholipid complex may include injecting the APOA1 mimetic peptide/phospholipid complex in the subject.
  • dosages in this case are of from about 1 ⁇ g to about 10 g per kg body weight of the subject, about 1 mg to about .5 g per kg body weight of the subject, and about 25 mg per kg body weight of the subject.
  • these compounds include peptides, or analogues thereof, which are capable of forming amphipathic alpha-helices in the presence of lipids and which mimic the activity of APOA1. They are therefore referred-to as APOA1 agonists.
  • the agonists have as their main feature a "core" peptide composed of 15 to 29 amino acid residues, preferably 22 amino acid residues, or an analogue thereof wherein at least one amide linkage in the peptide is replaced with a substituted amide, an isostere of an amide or an amide mimetic.
  • APOA1 agonists are based, in part, on the discovery that altering certain amino acid residues in the primary sequence of the 22-mer consensus sequence disclosed in Venkatachalapathi et al., 1991 , MoI. Conformation and Biol. Interactions, Indian Acad. Sci. B: 585-596 (PVLDEFREKLNEELEALKQKLK; hereinafter "Seg rest's consensus 22-mer” or “consensus 22-mer”) that were thought to be critical for activity, yields synthetic peptides which exhibit activities that approach, or in some embodiments even exceed, the activity of native APOA1.
  • Diastolic dysfunction classification was compared across groups using chi- square test. All analyses were done with SAS version 9.1 (SAS Institute Inc., Cary, NC, USA) and conducted at the 0.05 significance level.
  • HDL-based therapy such as for example one or more infusion(s) or bolus(es) of HDL or peptide (with or without lipids) with HDL-like effects, orally administered HDL-mimetic agents, and/or the administration of cholesteryl ester transfer protein (CETP) modulators, or scavenger receptor class B, member 1 (SRB1) modulators or liver X receptor (LXR)/retinoid X receptor (RXR) agonists, or ATP-binding cassette transporter-1 (ABCA1) agonists, or peroxisome proliferator- activated receptor (PPAR) agonists, among others.
  • CETP cholesteryl ester transfer protein
  • SRB1 scavenger receptor class B
  • SRB1 scavenger receptor class B
  • LXR liver X receptor
  • RXR retinoid X receptor
  • ABCA1 ATP-binding cassette transporter-1
  • PPAR peroxisome proliferator- activated receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur un procédé de traitement d'un dysfonctionnement diastolique, chez un mammifère, qui comporte l'administration d'une quantité thérapeutiquement efficace d'un agoniste inverse de transport de lipide audit mammifère. L'agoniste idéal est un complexe peptide/phospholipide mimétique de l'apolipoprotéine-A1 (APOA1).
PCT/CA2010/000108 2009-01-23 2010-01-25 Procédé de prévention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimétique de l'apolipoprotéine-a1 (apoa1) WO2010083611A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10733186A EP2389189A4 (fr) 2009-01-23 2010-01-25 Procédé de prévention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimétique de l'apolipoprotéine-a1 (apoa1)
CA2788223A CA2788223A1 (fr) 2009-01-23 2010-01-25 Procede de prevention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimetique de l'apolipoproteine-a1 (apoa1)
US13/185,737 US20120021982A1 (en) 2009-01-23 2011-07-19 Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20205109P 2009-01-23 2009-01-23
US61/202,051 2009-01-23
US20219109P 2009-02-05 2009-02-05
US61/202,191 2009-02-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/185,737 Continuation-In-Part US20120021982A1 (en) 2009-01-23 2011-07-19 Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction

Publications (1)

Publication Number Publication Date
WO2010083611A1 true WO2010083611A1 (fr) 2010-07-29

Family

ID=42355467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2010/000108 WO2010083611A1 (fr) 2009-01-23 2010-01-25 Procédé de prévention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimétique de l'apolipoprotéine-a1 (apoa1)

Country Status (3)

Country Link
EP (1) EP2389189A4 (fr)
CA (1) CA2788223A1 (fr)
WO (1) WO2010083611A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120021982A1 (en) * 2009-01-23 2012-01-26 Jean-Claude Tardif Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction
WO2012028526A2 (fr) 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Tétranectine-apolipoprotéine a-i, particules lipidiques la contenant et son utilisation
WO2013026860A1 (fr) 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Protéine hybride raccourcie tétranectine-apolipoprotéine a-i, particule lipidique la contenant, et utilisations associées
US9388232B2 (en) 2009-02-16 2016-07-12 Cerenis Therapeutics Holding Sa Apolipoprotein A-I mimics

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402975B2 (en) 2011-08-31 2016-08-02 Becton, Dickinson And Company Systems and methods to increase rigidity and snag-resistance of catheter tip

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6376464B1 (en) 1997-09-29 2002-04-23 Esperion Therapeutics, Inc. Lipid complexes of APO A-1 agonist compounds
US6506799B1 (en) 1999-04-01 2003-01-14 Esperion Therapeutics, Inc. Methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension with ether compounds
WO2007137400A1 (fr) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Méthode et composé pour le traitement des sténoses valvulaires

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376464B1 (en) 1997-09-29 2002-04-23 Esperion Therapeutics, Inc. Lipid complexes of APO A-1 agonist compounds
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6506799B1 (en) 1999-04-01 2003-01-14 Esperion Therapeutics, Inc. Methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension with ether compounds
WO2007137400A1 (fr) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Méthode et composé pour le traitement des sténoses valvulaires

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy, 20th Ed.,", 2003, LIPPINCOTT WILLIAMS & WILKINS
GALEMA, T.W. ET AL.: "Early detection of left ventricular dysfunction by doppler tissue imaging and N-terminal Pro-B-type natriuretic peptide in patients with symptomatic severe aortic stenosis.", J. AM. SOC. ECHOCARDIOGR., vol. 21, no. 3, March 2008 (2008-03-01), pages 257 - 261 *
See also references of EP2389189A4 *
VENKATACHALAPATHI ET AL.: "Mol. Conformation and Biol. Interactions", 1991, INDIAN ACAD. SCI. B, pages: 585 - 596
ZHANG, Z. ET AL.: "Apolipoprotein A-1 mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats.", AM. J. PHYSIOL. HEART CIRC. PHYSIOL., vol. 297, no. 2, August 2009 (2009-08-01), pages H866 - H873 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120021982A1 (en) * 2009-01-23 2012-01-26 Jean-Claude Tardif Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction
US9388232B2 (en) 2009-02-16 2016-07-12 Cerenis Therapeutics Holding Sa Apolipoprotein A-I mimics
US9981008B2 (en) 2009-02-16 2018-05-29 Cerenis Therapeutics Holding Sa Apolipoprotein A-I mimics
WO2012012870A1 (fr) * 2010-07-28 2012-02-02 Institut De Cardiologie De Montreal Compositions pharmaceutiques pour le traitement du dysfonctionnement diastolique ventriculaire gauche comprenant un complexe de peptides/phospholipides d'apolipoprotéines
WO2012028526A2 (fr) 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Tétranectine-apolipoprotéine a-i, particules lipidiques la contenant et son utilisation
WO2013026860A1 (fr) 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Protéine hybride raccourcie tétranectine-apolipoprotéine a-i, particule lipidique la contenant, et utilisations associées
US8791063B2 (en) 2011-08-25 2014-07-29 Hoffmann-La Roche, Inc. Shortened tetranectin-apolipoprotein A-I fusion protein, a lipid particle containing it, and uses thereof
US9139640B2 (en) 2011-08-25 2015-09-22 Hoffmann-La Roche Inc. Shortened tetranectin-apolipoprotein A-1 fusion protein, a lipid particle containing it, and uses thereof

Also Published As

Publication number Publication date
EP2389189A4 (fr) 2012-12-19
CA2788223A1 (fr) 2010-07-29
EP2389189A1 (fr) 2011-11-30

Similar Documents

Publication Publication Date Title
Degoma et al. Novel HDL-directed pharmacotherapeutic strategies
Kamagate et al. FoxO1 integrates insulin signaling to VLDL production
US20180203025A1 (en) Hdl therapy markers
S Getz et al. HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders
JP5954736B2 (ja) 難治性炎症性腸疾患の予防又は治療方法
Reddy et al. Apolipoprotein AI mimetics
US8163699B2 (en) Method for the treatment of valvular disease
JP2008534487A (ja) 荷電リポタンパク質複合体およびその使用
EP2389189A1 (fr) Procédé de prévention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimétique de l'apolipoprotéine-a1 (apoa1)
TW200808335A (en) Methods for the treatment of macular degeneration and related eye conditions
Verdier et al. Targeting high-density lipoproteins: update on a promising therapy
Zhang et al. Calcium desensitizer catechin reverses diastolic dysfunction in mice with restrictive cardiomyopathy
Lehrke et al. Cardiovascular effects of incretin-based therapies
Xie et al. ABCA1 plays no role in the centripetal movement of cholesterol from peripheral tissues to the liver and intestine in the mouse
US9504700B2 (en) Methods and compositions for stimulation and enhancement of regeneration of tissues
JP2022064986A (ja) Ｌｌｐ２ａ－ビスホスホネート化合物を用いて骨壊死を処置する方法
Brousseau Emerging role of high-density lipoprotein in the prevention of cardiovascular disease
US20170007624A1 (en) Methods and compositions for stimulation and enhancement of regeneration of tissues
WO2007096745A1 (fr) Methodes de traitement de la degenerescence maculaire et de pathologies de l'oeil associees
Chiesa et al. Acute effects of high-density lipoproteins: biochemical basis and clinical findings
WO2017120568A1 (fr) Compositions de peptides mimétiques de l'apoe
US20150150939A1 (en) Apolipoprotein Mixtures
CN109310737B (zh) 治疗代谢疾病的组合物和方法
Hutt et al. Medical Treatment Strategies for Hypertrophic Cardiomyopathy
Cham Not All “BAD” Cholesterol Carriers Are Necessarily Bad and Not All “GOOD” Cholesterol Carriers Are as Good as Can Be: Plasma Delipidation, a Non-Pharmacological Treatment for Atherosclerosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10733186

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010733186

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2788223

Country of ref document: CA